323 related articles for article (PubMed ID: 18320119)
1. [Effectiveness of prophylaxis against tuberculosis in patients infected with HIV].
Arbeláez MP; Arbeláez A; Gómez RD; Rojas C; Vélez L; Arias SL; Nagles J; Peláez LM; Betancourt G; Velásquez G
Biomedica; 2007 Dec; 27(4):515-25. PubMed ID: 18320119
[TBL] [Abstract][Full Text] [Related]
2. Isoniazid preventive therapy in human immunodeficiency virus-infected persons. Long-term effect on development of tuberculosis and survival.
Moreno S; Miralles P; Diaz MD; Baraia J; Padilla B; Berenguer J; Alberdi JC
Arch Intern Med; 1997 Aug 11-25; 157(15):1729-34. PubMed ID: 9250234
[TBL] [Abstract][Full Text] [Related]
3. Long term follow up of HIV-infected patients with tuberculosis treated with 6-month intermittent short course chemotherapy.
Swaminathan S; Deivanayagam CN; Rajasekaran S; Venkatesan P; Padmapriyadarsini C; Menon PA; Ponnuraja C; Dilip M
Natl Med J India; 2008; 21(1):3-8. PubMed ID: 18472696
[TBL] [Abstract][Full Text] [Related]
4. Effect of isoniazid chemoprophylaxis on HIV-related mycobacterial disease.
Graham NM; Galai N; Nelson KE; Astemborski J; Bonds M; Rizzo RT; Sheeley L; Vlahov D
Arch Intern Med; 1996 Apr; 156(8):889-94. PubMed ID: 8774208
[TBL] [Abstract][Full Text] [Related]
5. Changes in HIV RNA viral load, CD4+ T-cell counts, and levels of immune activation markers associated with anti-tuberculosis therapy and cotrimoxazole prophylaxis among HIV-infected tuberculosis patients in Abidjan, Cote d'Ivoire.
Kalou M; Sassan-Morokro M; Abouya L; Bile C; Maurice C; Maran M; Tossou O; Roels T; Greenberg AE; Wiktor SZ; Nkengasong JN
J Med Virol; 2005 Feb; 75(2):202-8. PubMed ID: 15602734
[TBL] [Abstract][Full Text] [Related]
6. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study.
Spyridis NP; Spyridis PG; Gelesme A; Sypsa V; Valianatou M; Metsou F; Gourgiotis D; Tsolia MN
Clin Infect Dis; 2007 Sep; 45(6):715-22. PubMed ID: 17712755
[TBL] [Abstract][Full Text] [Related]
7. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis.
Gao XF; Wang L; Liu GJ; Wen J; Sun X; Xie Y; Li YP
Int J Tuberc Lung Dis; 2006 Oct; 10(10):1080-90. PubMed ID: 17044199
[TBL] [Abstract][Full Text] [Related]
8. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study.
Page KR; Sifakis F; Montes de Oca R; Cronin WA; Doherty MC; Federline L; Bur S; Walsh T; Karney W; Milman J; Baruch N; Adelakun A; Dorman SE
Arch Intern Med; 2006 Sep; 166(17):1863-70. PubMed ID: 17000943
[TBL] [Abstract][Full Text] [Related]
9. Effect of isoniazid prophylaxis on incidence of active tuberculosis among Thai HIV-infected individuals.
Saenghirunvattana S
J Med Assoc Thai; 1996 May; 79(5):285-7. PubMed ID: 8708519
[TBL] [Abstract][Full Text] [Related]
10. 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity.
Ziakas PD; Mylonakis E
Clin Infect Dis; 2009 Dec; 49(12):1883-9. PubMed ID: 19911936
[TBL] [Abstract][Full Text] [Related]
11. Reduction of clinical tuberculosis in HIV-infected males with isoniazid prophylaxis.
Alaei K; Alaei A; Mansouri D
East Mediterr Health J; 2002 Nov; 8(6):754-7. PubMed ID: 15568452
[TBL] [Abstract][Full Text] [Related]
12. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS.
Gordin FM; Matts JP; Miller C; Brown LS; Hafner R; John SL; Klein M; Vaughn A; Besch CL; Perez G; Szabo S; El-Sadr W
N Engl J Med; 1997 Jul; 337(5):315-20. PubMed ID: 9233868
[TBL] [Abstract][Full Text] [Related]
13. Influence of the human immunodeficiency virus in the incidence of tuberculosis in a cohort of intravenous drug users: effectiveness of anti-tuberculosis chemoprophylaxis.
Jansà JM; Serrano J; Caylà JA; Vidal R; Ocaña I; Español T
Int J Tuberc Lung Dis; 1998 Feb; 2(2):140-6. PubMed ID: 9580481
[TBL] [Abstract][Full Text] [Related]
14. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis.
Ena J; Valls V
Clin Infect Dis; 2005 Mar; 40(5):670-6. PubMed ID: 15714411
[TBL] [Abstract][Full Text] [Related]
15. Declining prevalence of drug-resistant tuberculosis among HIV/tuberculosis co-infected patients receiving antiretroviral therapy.
Sungkanuparph S; Eampokalap B; Chottanapund S; Bed ST; Manosuthi W
J Med Assoc Thai; 2007 May; 90(5):884-8. PubMed ID: 17596041
[TBL] [Abstract][Full Text] [Related]
16. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
[TBL] [Abstract][Full Text] [Related]
17. [Compliance, tolerance and effectiveness of a short chemoprophylaxis regimen for the treatment of tuberculosis].
Martínez Alfaro E; Solera J; Serna E; Cuenca D; Castillejos ML; Espinosa A; Sáez L
Med Clin (Barc); 1998 Oct; 111(11):401-4. PubMed ID: 9834911
[TBL] [Abstract][Full Text] [Related]
18. Influence of highly active anti-retroviral therapy (HAART) on the natural history of extra-pulmonary tuberculosis in HIV patients.
García de Olalla P; Martínez-González MA; Caylà JA; Jansà JM; Iglesias B; Guerrero R; Marco A; Gatell JM; Ocaña I;
Int J Tuberc Lung Dis; 2002 Dec; 6(12):1051-7. PubMed ID: 12546112
[TBL] [Abstract][Full Text] [Related]
19. No evidence for multiple-drug prophylaxis for tuberculosis compared with isoniazid alone in Southeast Asian refugees and migrants: completion and compliance are major determinants of effectiveness.
MacIntyre CR; Ansari MZ; Carnie J; Hart WG
Prev Med; 2000 May; 30(5):425-32. PubMed ID: 10845752
[TBL] [Abstract][Full Text] [Related]
20. Virological response to highly active antiretroviral therapy is unaffected by antituberculosis therapy.
Breen RA; Miller RF; Gorsuch T; Smith CJ; Ainsworth J; Ballinger J; Swaden L; Cropley I; Johnson MA; Lipman MC
J Infect Dis; 2006 May; 193(10):1437-40. PubMed ID: 16619192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
